MétaCan
Menu
Back to cohort
Record W4417278693 · doi:10.51731/cjht.2025.1303

Vorasidenib (Voranigo)

2025· article· W4417278693 on OpenAlexaboutno aff
CDA-AMC

Bibliographic record

VenueCanadian Journal of Health Technologies · 2025
Typearticle
Language
FieldMedicine
TopicGlioma Diagnosis and Treatment
Canadian institutionsnot available
Fundersnot available
KeywordsOligodendrogliomaReimbursementIDH2AstrocytomaGrading (engineering)IDH1Radiation therapyQuality of life (healthcare)

Abstract

fetched live from OpenAlex

Canada’s Drug Agency (CDA-AMC) recommends that Voranigo be reimbursed by public drug plans for patients aged 12 years and older with grade 2 (WHO 2016, 2021 grading system) astrocytoma or oligodendroglioma with a susceptible IDH1 mutation or IDH2 mutation who are not in immediate need of radiotherapy and/or chemotherapy following surgical intervention if certain conditions are met. The pan-Canadian Oncology Drug Review Expert Review Committee (pERC) determined that Voranigo demonstrates acceptable clinical value compared with active surveillance in patients with grade 2 astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations. This determination was sufficient for pERC to recommend that Voranigo be reimbursed. Given that Voranigo is expected to be an additive treatment to active surveillance, acceptable clinical value refers to added value versus active surveillance. Evidence from a clinical trial (INDIGO; N = 331) demonstrated that, when compared to active surveillance, treatment with Voranigo likely resulted in added clinical benefit in progression-free survival (PFS) and time to next intervention (TTNI) in patients aged 12 years and older with grade 2 oligodendroglioma or astrocytoma with a susceptible IDH1 or IDH2 mutation who were not in immediate need of radiotherapy and/or chemotherapy. Key limitations of the evidence were the short duration of follow-up, which prevented pERC from drawing conclusions on the impact of Voranigo on overall survival (OS), and the large amount of missing data for health-related quality of life (HRQoL) outcomes.The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. Voranigo should only be covered for patients aged 12 years and older with grade 2 (WHO 2016, 2021 grading system) astrocytoma or oligodendroglioma with a susceptible IDH1 mutation or IDH2 mutation who have had at least 1 prior surgery for glioma, have measurable and/or evaluable disease at the time of initiation of therapy, and are not in immediate need of radiotherapy or chemotherapy, in line with the sponsor’s reimbursement request. Patients should also have good performance status and must not have grade 3 tumours or tumours with high-risk features, prior anticancer therapy for glioma other than surgery, or current therapeutic steroid use for glioma.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Other · Consensus signal: none
Teacher disagreement score0.011
Threshold uncertainty score0.036

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.001
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0110.002

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.022
GPT teacher head0.309
Teacher spread0.288 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreOther

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueCanadian Journal of Health TechnologiesSame topicGlioma Diagnosis and TreatmentFrench-language works237,207